asunaprevir   Click here for help

GtoPdb Ligand ID: 10882

Synonyms: BMS-650032 | BMS650032 | compound 24 [PMID: 24564672] | Sunvepra™
Approved drug PDB Ligand
asunaprevir is an approved drug (Japan (2014), Canada (2016))
Compound class: Synthetic organic
Comment: Asunaprevir (BMS-650032) is an orally bioavailable, oligopeptide-based inhibitor of the nonstructural protein 3 (NS3), from hepatitis C virus (HCV) [4]. NS3, is a serine protease that is essential for proteolytic cleavages within the HCV polyprotein, a function that is key during HCV viral RNA replication. More recently asunaprevir has been reported to inhibit the papain-like protease (PL-pro, nsp3) in a number of coronaviruses [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 3
Rotatable bonds 18
Topological polar surface area 190.71
Molecular weight 747.27
XLogP 4.41
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@H](C(C)(C)C)NC(=O)OC(C)(C)C)Oc1ncc(c2c1cc(Cl)cc2)OC)C(=O)NS(=O)(=O)C1CC1
Isomeric SMILES C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@H](C(C)(C)C)NC(=O)OC(C)(C)C)Oc1ncc(c2c1cc(Cl)cc2)OC)C(=O)NS(=O)(=O)C1CC1
InChI InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
1. Akamatsu N, Sugawara Y, Kokudo N. (2015)
Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Expert Rev Anti Infect Ther, 13 (11): 1307-17. [PMID:26414905]
2. Anson BJ, Chapman ME, Lendy EK, Pshenychnyi S, D’Aquila RT, Satchell KJF, Mesecar AD. (2020)
Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs.
Nature Research, PrePrint, Under Review. DOI: 10.21203/
3. Bristol Myers Squibb. 
Bristol-Myers Squibb Statement about Asunaprevir in the U.S.
Accessed on 19/05/2020. Modified on 19/05/2020.,
4. Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM et al.. (2014)
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
J Med Chem, 57 (5): 1730-52. [PMID:24564672]